ACIP Dengue Vaccine Workgroup

Wilbur Chen, MD, MSc Katherine A. Poehling, MD, MPH ACIP Members and Workgroup Co-Chairs Advisory Committee on Immunization Practices ACIP Meeting June 23, 2021

ACIP Dengue Vaccines Workgroup

ACIP Members

Kathy Poehling (Co-chair) Wilbur Chen (Co-Chair) Beth Bell Veronica McNally

<u>CDC Lead</u> Gabriela Paz-Bailey

<u>Ex Officio Members</u> Kaitlyn Morabito (NIH) Ralph LeBlanc (FDA) Kirk Prutzman (FDA) Srihari Seshadri (DOD) <u>Liaison Representatives</u> Elizabeth Barnett (AAP) Rob Schechter (AIM)

Consultants Edwin Asturias Robert Atmar Alan Barrett Anna Durbin Ines Esquilin Tony Marfin Hal Margolis Kristen Pierce Anita Shet

Steve Waterman

CDC Contributors

Laura Adams

Mimi Eckert

Rachel Eidex

Susan Hills


Terri Hyde

Mike McNeil

Jorge Munoz

Erin Staples Cindy Weinbaum

Dengvaxia timeline



Dengue vaccine workgroup timeline

2019 Phase 3 results

2021

2017 Dengue epi and vaccine development		Safety & pharmacovigilance GRADE Cost effectiveness Dengue Diagnostics Partially effective vaccines Dengue vaccine in Philippines VRBPAC review FDA approval		Dengue IgG test evaluation Evidence to recommendations framework (EtR) Recommendations to ACIP
	2018 WG on hold		2020	

wg on noid Flavivirus WG split Dengue Vaccine Workgroup is formed

Vaccine acceptability WHO global position Feasibility Health Equity

February 24-25, 2021 Importance of a specific test for pre-vaccination screening

- CYD-TCV vaccine presents novel challenges due to requirement of pre-vaccination screening
- A test for pre-vaccination dengue screening needs to be specific to minimize vaccination of seronegative children and sensitive to maximize identification of children who can benefit from the vaccine
- CDC evaluated commercially available tests and identified one ELISA tests and two versions of a rapid test with high specificity and sensitivity
- Test performance characteristics in the MMWR with ACIP recommendations and on CDC website

May 5, 2021

Evidence to recommendations framework

Consensus from ACIP Dengue Vaccine Workgroup

- Dengue is an important public health problem
- Dengvaxia is an effective vaccine for seropositive children ages 9-16 years
- Balance of benefits and risks favors benefits
- Acceptable to target population and stakeholders
- Cost-effective strategy under the expected seroprevalence scenarios
- Will increase health equity
- Feasible to implement
- Proposal for routine recommendation for children 9-16 years

ACIP Schedule 2021

ACIP June 2021 Meeting VOTE Dengvaxia recommendations

Presentations today

Acceptability of dengue vaccine in Puerto Rico Dr. Ines Esquilin, Professor, University of Puerto Rico, School of Medicine Implementation of dengue vaccine in Puerto Rico Dr. Iris Cardona, Chief Medical Officer, Department of Health, Puerto Rico Dengue vaccine draft recommendations using the evidence to recommendation framework Dr. Gabriela Paz-Bailey, CDC, NCEZID, DVBD